Mitomycine Medac (Mitomycin)

Mitomycin is used as intravesical chemotherapy for bladder cancer, targeting superficial disease to prevent recurrence.

• Non‑muscle‑invasive bladder cancer: after transurethral resection, intravesical Mitomycin reduces the likelihood of tumor recurrence and delays progression to muscle‑invasive disease.
• Carcinoma in situ of the bladder: administered weekly, Mitomycin can induce complete remission in a substantial proportion of patients, preserving bladder function.
• Recurrent superficial bladder tumors: Mitomycin provides a local cytotoxic effect that eradicates residual malignant cells and lowers the risk of further recurrences.

• Mitomycin exerts its antineoplastic activity by undergoing enzymatic reduction within tumor cells to generate reactive intermediates that form covalent cross‑links between DNA strands. These interstrand cross‑links block DNA replication and transcription, ultimately triggering apoptosis of rapidly dividing malignant cells while sparing most normal tissues. The drug preferentially accumulates in hypoxic tumor microenvironments, enhancing its selectivity, and its alkylating action leads to irreversible DNA damage that the cell cannot repair.

Mitomycin administered intravesically may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Irritative bladder symptoms: dysuria, urgency, and frequency.
• Hematuria: visible blood in urine.
• Mild cystitis: inflammation causing discomfort.
• Nausea: occasional feeling of queasiness.
• Transient renal function changes: slight increase in serum creatinine.

Serious or Rare Side Effects

• Severe cystitis or bladder ulceration: may require treatment interruption.
• Systemic absorption leading to bone marrow suppression: neutropenia or thrombocytopenia.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Pulmonary toxicity: interstitial pneumonitis in rare cases.

When using Mitomycine Medac, clinicians should observe specific safety measures to minimize risks.

• Patient selection: confirm diagnosis of non‑muscle‑invasive bladder cancer before therapy.
• Renal function: assess baseline creatinine and monitor during treatment.
• Bladder integrity: avoid use in patients with active urinary tract infection or gross hematuria.
• Hematologic monitoring: perform complete blood counts to detect systemic absorption effects.
• Concomitant chemotherapy: evaluate potential additive toxicity when combined with other cytotoxics.
• Store at room temperature: keep the solution in the original container, protect from light and moisture.

Mitomycin may interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

• Strong oxidizing agents: may inactivate Mitomycin and reduce therapeutic effect.
• High-dose radiation therapy to the pelvis: increases risk of severe bladder toxicity.

Moderate Interactions (Monitor Closely)

• Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): may exacerbate renal impairment.
• Myelosuppressive agents (e.g., cyclophosphamide): heightened risk of bone‑marrow suppression.
• Antifolate drugs (e.g., methotrexate): potential additive cytotoxicity.
• CYP450 inducers: may alter metabolic activation of Mitomycin.